Jillian Evanko: As we commented on slide 18, we are pleased with the availability of our main material input costs, as well as the trend we’ve seen in the tempering of those three. And the way we’ve built the forecast is assuming that where we sit today is where the input costs continue to be for the year. So additional tempering would be a positive. In addition to that, as Brinkman mentioned in our prepared remarks, we are holding price and we do intend to address specific surgical price increases further as we get through 2023. And we’ve already done some of that in January of this year. Joe, anything you want to add on sourcing?
Joe Brinkman: Just as we talked about on slide 18, definitely seeing more stability on the main input costs, primarily the metals there. And unforeseen events in the world can adjust that. But right now we’re seeing stability and better availability, which is reinforcing our pricing approach and our margin improvement that we’ve already seen take hold here and will continue to take hold. And then just going back to the previous energy comments, significant insourcing opportunities related to the Howden acquisition that are going to generate additional material cost out moving forward through these insourcing synergies. So, another positive for us.
Jillian Evanko: And all that ties to the back end of your question of working capital opportunity ahead. So, we’ve had inflated inventory levels in 2021 and 2022, and we have good line of sight of not needing to keep those inflated levels in 2023 and driving inventory reduction, as well as applying the best practices that Howden has had in improving their working capital as a percent of sales to the Chart working capital business. So, all in all, the setup for 2023, we have good visibility to the input costs, good visibility to the demand and the sale, and so we feel confident in being able to deliver the outlook that we’ve provided.
Operator: And our next question comes from Chase Mulvehill from Bank of America.
Chase Mulvehill: I’ll ask my follow-up real quick. And I just want to ask on margins. Obviously, we can back into the margin number for 2023, which is a pretty solid €“ strong, 21.5% at the midpoint for EBITDA margins is what’s implied in your guidance. But can I ask, specifically, on specialty product margins? In the fourth quarter, they took a step down, but if I look at the last few fourth quarters, they stepped out. I don’t know if there’s some seasonality in that. But it’s is really kind of the question on 2023 in specialty product margins. How should we be thinking about margins in 2023 for specialty products?
Jillian Evanko: You’re absolutely right in in your implied 21.5% midpoint on EBITDA and we feel really good about it. We are just thrilled with where the sequential margins went in the fourth quarter and being driven by the operational side of the business versus below the line items. So, all of that’s a positive setup. With that said on the specialty, you’re correct. First of all, Q4 tends to be that way, which is driven by the book and ship element of the specialty business, but the reality in this particular Q4, if you compared to the prior Q4 of 2021, the biggest driver was HLNG volume change, which the margins are nice on that. But if you looked at it in absolute Q4 of 2022, we had just under $10 million of revenue that was associated with first-of-a-kind project that actually came in inside the quarter.
